Tag: pemigatinib

Latest News

Samenvatting: FDA keurt Incyte’s Pemazyre ™ (pemigatinib) goed als eerste gerichte behandeling voor volwassenen met eerder behandeld, inoperabel lokaal gevorderd of gemetastaseerd cholangiocarcinoom

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq: INCY) heeft vandaag aangekondigd dat de Amerikaanse Food en Drug Administration (FDA) Pemazyre ™ (pemigatinib) heeft goedgekeurd, een kinaseremmer die is...
Latest News

FDA erteilt Zulassung für Pemazyre™ (Pemigatinib) von Incyte als erste gezielte Therapie für Erwachsene mit vorbehandeltem, inoperablem, lokal fortgeschrittenem oder metastasierendem Cholangiokarzinom

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) die Zulassung für Pemazyre™ (Pemigatinib) erteilt hat. Dabei handelt es...
Latest News

Le Pemazyre™ (pemigatinib) d’Incyte reçoit l’approbation de la FDA comme premier traitement ciblé pour les adultes atteints d’un cholangiocarcinome localement avancé ou métastatique, non résécable et déjà traité

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) a annoncé aujourd’hui que la Food and Drug Administration (FDA) américaine a approuvé l’utilisation du Pemazyre™ (pemigatinib), un inhibiteur de kinases...
Latest News

 FDA Approves Incyte’s Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre™ (pemigatinib), a kinase inhibitor indicated for the treatment...
Latest News

Riassunto:  La FDA approva Pemazyre™ (pemigatinib) di Incyte come prima terapia mirata per adulti affetti da colangiocarcinoma metastatico o avanzato che non può essere sottoposto localmente a resezione, già trattato

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) oggi ha annunciato che la FDA (Food and Drug Administration, l’agenzia federale statunitense per gli alimenti e i farmaci) ha approvato...
Latest News

Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for Pemazyre™ (pemigatinib), the First FDA-Approved Targeted Therapy for Adults with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx as the registrational companion diagnostic for Incyte’s Pemazyre™...
Latest News

Incyte veröffentlicht positive Interimsdaten aus einer Phase-2-Studie zu Pemigatinib, seinem selektiven FGFR-Hemmer bei Patienten mit Cholangiokarzinom

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) gab aktualisierte Daten aus seiner FIGHT-202-Studie der Phase 2 zu Evaluierung von Pemigatinib (INCB54828), einem selektiven Hemmer des Fibroblasten-Wachstumsfaktors (FGFR),...
Latest News

Incyte annonce des résultats intermédiaires positifs de l'essai de phase II du Pemigatinib, son inhibiteur sélectif de FGFR, chez les patients atteints de cholangiocarcinome

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) annonce des résultats actualisés de son étude de phase 2 en cours, FIGHT-202, évaluant le pemigatinib (INCB54828), son inhibiteur sélectif...
Latest News

Incyte annuncia dati intermedi positivi dello studio di fase 2 su pemigatinib, il suo inibitore selettivo dell'FGFR, nei pazienti con colangiocarcinoma

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) annuncia dati aggiornati dello studio di fase 2 FIGHT-202, in corso di svolgimento, per la valutazione di pemigatinib (INCB54828), il...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World